A novel approach to evaluation of tumor response for advanced pulmonary adenocarcinoma using the intertumoral heterogeneity response score

Abstract

Treatment response and prognosis estimation in advanced pulmonary adenocarcinoma are challenged by the significant heterogeneity of the disease. The current Response Evaluation Criteria in Solid Tumors (RECIST) criteria, despite providing a basis for solid tumor response evaluation, do not fully encompass this heterogeneity. To better represent these nuances, we introduce the intertumoral heterogeneity response score (THRscore), a measure built upon and expanding the RECIST criteria. This retrospective study included patients with 3–10 measurable advanced lung adenocarcinoma lesions who underwent first-line chemotherapy or targeted therapy. The THRscore, derived from the coefficient of variation in size for each measurable tumor before and 4–6 weeks posttreatment, unveiled a correlation with patient outcomes. Specifically, a high THRscore was associated with shorter progression-free survival, lower tumor response rate, and a higher tumor mutation burden. These associations were further validated in an external cohort, confirming THRscore's effectiveness in stratifying patients based on progression risk and treatment response, and enhancing the utility of RECIST in capturing complex tumor behaviors in lung adenocarcinoma. These findings affirm the promise of THRscore as an enhanced tool for tumor response assessment in advanced lung adenocarcinoma, extending the RECIST criteria's utility.

Keywords

intertumoral heterogeneity / intertumoral heterogeneous response / lung adenocarcinoma / RECIST criteria

References

1	I Dagogo-Jack, AT Shaw. Tumour heterogeneity and resistance to cancer therapies. Nat Rev Clin Oncol. 2018;15(2):81-94.
2	AA Alizadeh, V Aranda, A Bardelli, et al. Toward understanding and exploiting tumor heterogeneity. Nat Med. 2015;21(8):846-853.
3	I Dagogo-Jack, AT Shaw. Tumour heterogeneity and resistance to cancer therapies. Nat Rev Clin Oncol. 2018;15(2):81-94.
4	RA Burrell, C Swanton. Tumour heterogeneity and the evolution of polyclonal drug resistance. Mol Oncol. 2014;8(6):1095-1111.
5	N McGranahan, C Swanton. Biological and therapeutic impact of intratumor heterogeneity in cancer evolution. Cancer Cell. 2015;27(1):15-26.
6	D Belloni, S Heltai, M Ponzoni, et al. Modeling multiple myeloma-bone marrow interactions and response to drugs in a 3D surrogate microenvironment. Haematologica. 2018;103(4):707-716.
7	RS Huang, MJ Ratain. Pharmacogenetics and pharmacogenomics of anticancer agents. CA Cancer J Clin. 2009;59(1):42-55.
8	F Petralia, N Tignor, B Reva, et al. Integrated proteogenomic characterization across major histological types of pediatric brain cancer. Cell. 2020;183(7):1962-1985. e31.
9	J Massagué, AC Obenauf. Metastatic colonization by circulating tumour cells. Nature. 2016;529(7586):298-306.
10	Z-F Lim, PC Ma. Emerging insights of tumor heterogeneity and drug resistance mechanisms in lung cancer targeted therapy. J Hematol Oncol. 2019;12(1):134.
11	M Gerlinger, AJ Rowan, S Horswell, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. New England Journal of Medicine. 2012;366(10):883-892.
12	P Therasse, SG Arbuck, EA Eisenhauer, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92(3):205-216.
13	EA Eisenhauer, P Therasse, J Bogaerts, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228-247.
14	ZY Dong, HR Zhai, QY Hou, et al. Mixed responses to systemic therapy revealed potential genetic heterogeneity and poor survival in patients with non-small cell lung cancer. Oncologist. 2017;22(1):61-69.
15	SB Goldberg, GR Oxnard, S Digumarthy, et al. Chemotherapy with erlotinib or chemotherapy alone in advanced non-small cell lung cancer with acquired resistance to EGFR tyrosine kinase inhibitors. Oncologist. 2013;18(11):1214-1220.
16	H Wang, J Huang, X Yu, et al. Different efficacy of EGFR tyrosine kinase inhibitors and prognosis in patients with subtypes of EGFR-mutated advanced non-small cell lung cancer: a meta-analysis. J Cancer Res Clin Oncol. 2014;140:1901-1909.
17	RL Wahl, H Jacene, Y Kasamon, MA Lodge. From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med. 2009;50:122s-150s. Suppl 1(Suppl 1).
18	L Seymour, J Bogaerts, A Perrone, et al. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol. 2017;18(3):e143-e152.
19	CE Brown. Coefficient of variation. Applied Multivariate Statistics in Geohydrology and Related Sciences. Springer; 1998:155-157.
20	GF Reed, F Lynn, BD Meade. Use of coefficient of variation in assessing variability of quantitative assays. Clin Vaccine Immunol. 2002;9(6):1235-1239.
21	D Medvigy, C Beaulieu. Trends in daily solar radiation and precipitation coefficients of variation since 1984. J Climate. 2012;25(4):1330-1339.
22	JD Curto, JC Pinto. The coefficient of variation asymptotic distribution in the case of non-iid random variables. J Appl Stat. 2009;36(1):21-32.
23	KB Kordonsky, I Gertsbakh. Multiple time scales and the lifetime coefficient of variation: engineering applications. Lifetime Data Anal. 1997;3:139-156.
24	MJ Pencina, RB D'Agostino, RB D'Agostino, RS Vasan. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med. 2008;27(2):157-172. discussion 207–12.
25	PG Shields, RS Herbst, D Arenberg, et al. Smoking cessation, version 1.2016, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2016;14(11):1430-1468.
26	A Mayakonda, DC Lin, Y Assenov, C Plass, HP Koeffler. Maftools: efficient and comprehensive analysis of somatic variants in cancer. Genome Res. 2018;28(11):1747-1756.
27	GM Blumenthal, SW Karuri, H Zhang, et al. Overall response rate, progression-free survival, and overall survival with targeted and standard therapies in advanced non-small-cell lung cancer: uS Food and Drug Administration trial-level and patient-level analyses. J Clin Oncol. 2015;33(9):1008-1014.
28	RK Jain, JJ Lee, C Ng, et al. Change in tumor size by RECIST correlates linearly with overall survival in phase I oncology studies. J Clin Oncol. 2012;30(21):2684-2690.
29	SL Mushti, F Mulkey, R Sridhara. Evaluation of overall response rate and progression-free survival as potential surrogate endpoints for overall survival in immunotherapy trials. Clin Cancer Res. 2018;24(10):2268-2275.
30	K Cooper, P Tappenden, A Cantrell, K Ennis. A systematic review of meta-analyses assessing the validity of tumour response endpoints as surrogates for progression-free or overall survival in cancer. Br J Cancer. 2020;123(11):1686-1696.
31	O Ciani, M Buyse, R Garside, et al. Meta-analyses of randomized controlled trials show suboptimal validity of surrogate outcomes for overall survival in advanced colorectal cancer. J Clin Epidemiol. 2015;68(7):833-842.
32	A Marusyk, K Polyak. Tumor heterogeneity: causes and consequences. Biochim Biophys Acta. 2010;1805(1):105-117.
33	D Hanahan, RA Weinberg. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646-674.
34	BM Faltas, D Prandi, ST Tagawa, et al. Clonal evolution of chemotherapy-resistant urothelial carcinoma. Nat Genet. 2016;48(12):1490-1499.
35	N Murugaesu, GA Wilson, NJ Birkbak, et al. Tracking the genomic evolution of esophageal adenocarcinoma through neoadjuvant chemotherapy. Cancer Discov. 2015;5(8):821-831.
36	A Sweeney, C Jiggins, S Johnsen. Insect communication: polarized light as a butterfly mating signal. Nature. 2003;423(6935):31-32.
37	K Xu, B Li, KA McGinnis, et al. Genome-wide association study of smoking trajectory and meta-analysis of smoking status in 842,000 individuals. Nat Commun. 2020;11(1):5302.
38	CC Maley, PC Galipeau, JC Finley, et al. Genetic clonal diversity predicts progression to esophageal adenocarcinoma. Nat Genet. 2006;38(4):468-473.
39	ZF Lim, PC Ma. Emerging insights of tumor heterogeneity and drug resistance mechanisms in lung cancer targeted therapy. J Hematol Oncol. 2019;12(1):134.
40	L Brady, M Kriner, I Coleman, et al. Inter- and intra-tumor heterogeneity of metastatic prostate cancer determined by digital spatial gene expression profiling. Nature Communications. 2021;12(1):1426.
41	Y Momozawa, R Sasai, Y Usui, et al. Expansion of cancer risk profile for BRCA1 and BRCA2 pathogenic variants. JAMA Oncol. 2022;8(6):871-878.
42	P Nombela, R Lozano, A Aytes, J Mateo, D Olmos, E Castro. BRCA2 and other DDR genes in prostate cancer. Cancers (Basel). 2019;11(3):352.
43	W Zhang, DC van Gent, L Incrocci, WM van Weerden, J Nonnekens. Role of the DNA damage response in prostate cancer formation, progression and treatment. Prostate Cancer Prostatic Dis. 2020;23(1):24-37.
44	R Lozano, E Castro, IM Aragón, et al. Genetic aberrations in DNA repair pathways: a cornerstone of precision oncology in prostate cancer. Br J Cancer. 2021;124(3):552-563.
45	M Jiang, K Jia, L Wang, et al. Alterations of DNA damage response pathway: biomarker and therapeutic strategy for cancer immunotherapy. Acta Pharm Sin B. 2021;11(10):2983-2994.
46	C Golias, A Charalabopoulos, K Charalabopoulos. Cell proliferation and cell cycle control: a mini review. Int J Clin Pract. 2004;58(12):1134-1141.
47	NA Seebacher, AE Stacy, GM Porter, AM Merlot. Clinical development of targeted and immune based anti-cancer therapies. J Exp Clin Cancer Res. 2019;38(1):156.
48	DS Salomon, R Brandt, F Ciardiello, N Normanno. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol/Hematol. 1995;19(3):183-232.
49	L Li, WB Neaves. Normal stem cells and cancer stem cells: the niche matters. Cancer Res. 2006;66(9):4553-4557.
50	S Sarkar, G Horn, K Moulton, et al. Cancer development, progression, and therapy: an epigenetic overview. Int J Mol Sci. 2013;14(10):21087-21113.
51	S Negrini, VG Gorgoulis, TD Halazonetis. Genomic instability — an evolving hallmark of cancer. Nat Rev Mol Cell Biol. 2010;11(3):220-228.
52	B Everitt. The Cambridge Dictionary of Statistics /B.S.Everitt. Cambridge University Press; 2002.
53	C Pélabon, CH Hilde, S Einum, M Gamelon. On the use of the coefficient of variation to quantify and compare trait variation. Evol Lett. 2020;4(3):180-188.
54	O Shechtman. The coefficient of variation as an index of measurement reliability. In: Doi SAR, Williams GM, eds. Methods of Clinical Epidemiology. SpringerBerlin Heidelberg; 2013:39-49.
55	T Hothorn, B Lausen. On the exact distribution of maximally selected rank statistics. Comput Stat Data Anal. 2003;43(2):121-137.
56	G Lin, C Li, PS Li, et al. Genomic origin and EGFR-TKI treatments of pulmonary adenosquamous carcinoma. Ann Oncol. 2020;31(4):517-524.
57	E Eden, R Navon, I Steinfeld, D Lipson, Z Yakhini. GOrilla: a tool for discovery and visualization of enriched GO terms in ranked gene lists. BMC Bioinformatics. 2009;10:48.
58	S Durrleman, R Simon. Flexible regression models with cubic splines. Stat Med. 1989;8(5):551-561.
59	H Uno, L Tian, T Cai, IS Kohane, LJ Wei. A unified inference procedure for a class of measures to assess improvement in risk prediction systems with survival data. Stat Med. 2013;32(14):2430-2442.
60	MJ Pencina, RB D'Agostino, EW Steyerberg. Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers. Stat Med. 2011;30(1):11-21.